Literature DB >> 10874060

The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections.

C S Wong1, S Jelacic, R L Habeeb, S L Watkins, P I Tarr.   

Abstract

BACKGROUND: Children with gastrointestinal infections caused by Escherichia coli O157:H7 are at risk for the hemolytic-uremic syndrome. Whether antibiotics alter this risk is unknown.
METHODS: We conducted a prospective cohort study of 71 children younger than 10 years of age who had diarrhea caused by E. coli O157:H7 to assess whether antibiotic treatment in these children affects the risk of the hemolytic-uremic syndrome and to assess the influence of confounding factors on this outcome. Estimates of relative risks were adjusted for possible confounding effects with the use of logistic-regression analysis.
RESULTS: Among the 71 children, 9 (13 percent) received antibiotics and the hemolytic-uremic syndrome developed in 10 (14 percent). Five of these 10 children had received antibiotics. Factors significantly associated with the hemolytic-uremic syndrome were a higher initial white-cell count (relative risk, 1.3; 95 percent confidence interval, 1.1 to 1.5), evaluation with stool culture soon after the onset of illness (relative risk, 0.3; 95 percent confidence interval, 0.2 to 0.8), and treatment with antibiotics (relative risk, 14.3; 95 percent confidence interval, 2.9 to 70.7). The clinical and laboratory characteristics of the 9 children who received antibiotics and the 62 who did not receive antibiotics were similar. In a multivariate analysis that was adjusted for the initial white-cell count and the day of illness on which stool was obtained for culture, antibiotic administration remained a risk factor for the development of the hemolytic uremic syndrome (relative risk, 17.3; 95 percent confidence interval, 2.2 to 137).
CONCLUSIONS: Antibiotic treatment of children with E. coli O157:H7 infection increases the risk of the hemolytic-uremic syndrome.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10874060      PMCID: PMC3659814          DOI: 10.1056/NEJM200006293422601

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  32 in total

1.  Risk factors for the progression of Escherichia coli O157:H7 enteritis to hemolytic-uremic syndrome.

Authors:  N Cimolai; J E Carter; B J Morrison; J D Anderson
Journal:  J Pediatr       Date:  1990-04       Impact factor: 4.406

2.  Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults.

Authors:  L J Goodman; G M Trenholme; R L Kaplan; J Segreti; D Hines; R Petrak; J A Nelson; K W Mayer; W Landau; G W Parkhurst
Journal:  Arch Intern Med       Date:  1990-03

3.  Escherichia coli O157:H7 and the hemolytic uremic syndrome: importance of early cultures in establishing the etiology.

Authors:  P I Tarr; M A Neill; C R Clausen; S L Watkins; D L Christie; R O Hickman
Journal:  J Infect Dis       Date:  1990-08       Impact factor: 5.226

4.  A severe outbreak of Escherichia coli O157:H7--associated hemorrhagic colitis in a nursing home.

Authors:  A O Carter; A A Borczyk; J A Carlson; B Harvey; J C Hockin; M A Karmali; C Krishnan; D A Korn; H Lior
Journal:  N Engl J Med       Date:  1987-12-10       Impact factor: 91.245

5.  Effect of subinhibitory concentrations of antibiotics on extracellular Shiga-like toxin I.

Authors:  J N Walterspiel; S Ashkenazi; A L Morrow; T G Cleary
Journal:  Infection       Date:  1992 Jan-Feb       Impact factor: 3.553

6.  Empiric treatment of acute diarrheal disease with norfloxacin. A randomized, placebo-controlled study. Swedish Study Group.

Authors:  J Wiström; M Jertborn; E Ekwall; K Norlin; B Söderquist; A Strömberg; R Lundholm; H Hogevik; L Lagergren; G Englund
Journal:  Ann Intern Med       Date:  1992-08-01       Impact factor: 25.391

7.  Hemolytic-uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations.

Authors:  A T Pavia; C R Nichols; D P Green; R V Tauxe; S Mottice; K D Greene; J G Wells; R L Siegler; E D Brewer; D Hannon
Journal:  J Pediatr       Date:  1990-04       Impact factor: 4.406

8.  Infections with Escherichia coli O157:H7 in Washington State. The first year of statewide disease surveillance.

Authors:  S M Ostroff; J M Kobayashi; J H Lewis
Journal:  JAMA       Date:  1989-07-21       Impact factor: 56.272

9.  Sorbitol-MacConkey medium for detection of Escherichia coli O157:H7 associated with hemorrhagic colitis.

Authors:  S B March; S Ratnam
Journal:  J Clin Microbiol       Date:  1986-05       Impact factor: 5.948

10.  The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli.

Authors:  M A Karmali; M Petric; C Lim; P C Fleming; G S Arbus; H Lior
Journal:  J Infect Dis       Date:  1985-05       Impact factor: 5.226

View more
  268 in total

1.  Escherichia coli O157:H7.

Authors:  E Weir
Journal:  CMAJ       Date:  2000-07-25       Impact factor: 8.262

2.  Escherichia coli infections and hemolytic-uremic syndrome.

Authors:  M Romney
Journal:  CMAJ       Date:  2001-05-15       Impact factor: 8.262

3.  Escherichia coli infections and hemolytic-uremic syndrome.

Authors:  N Cimolai
Journal:  CMAJ       Date:  2001-05-15       Impact factor: 8.262

4.  E. coli, antibiotics and hemolytic-uremic syndrome in children.

Authors:  D Farquhar
Journal:  CMAJ       Date:  2000-08-22       Impact factor: 8.262

Review 5.  Bacteriophage control of bacterial virulence.

Authors:  Patrick L Wagner; Matthew K Waldor
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

6.  Genome analysis of a novel Shiga toxin 1 (Stx1)-converting phage which is closely related to Stx2-converting phages but not to other Stx1-converting phages.

Authors:  Toshio Sato; Takeshi Shimizu; Masahisa Watarai; Midori Kobayashi; Shigeyuki Kano; Takashi Hamabata; Yoshifumi Takeda; Shinji Yamasaki
Journal:  J Bacteriol       Date:  2003-07       Impact factor: 3.490

7.  Role of the laboratory in the diagnosis of enterohemorrhagic Escherichia coli infections.

Authors:  Sue C Kehl
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

Review 8.  Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Authors:  Saul Tzipori; Abhineet Sheoran; Donna Akiyoshi; Arthur Donohue-Rolfe; Howard Trachtman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

9.  Cardiac ischemia during hemolytic uremic syndrome.

Authors:  Meena Thayu; Wayne L Chandler; Srdjan Jelacic; Carrie A Gordon; Geoffrey L Rosenthal; Phillip I Tarr
Journal:  Pediatr Nephrol       Date:  2003-02-07       Impact factor: 3.714

Review 10.  Hemolytic uremic syndrome.

Authors:  Caterina Mele; Giuseppe Remuzzi; Marina Noris
Journal:  Semin Immunopathol       Date:  2014-02-14       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.